Measles Seroprevalence and Related Factors in Women Aged 15-49 Years Old, in Mersin, Turkey
,
Abstract
Background: If the mother is immune to measles, the infant is protected against measles infection after birth with maternal immunity. Therefore, the mother's immunity to measles is the most important factor in protecting the baby from measles in the first year. This study aimed to investigate measles seroprevalence and related factors in women between Oct 2019 and Jun 2021.
Methods: The cross-sectional study was conducted on women aged 15-49 yr in Mersin city. Overall, 400 people were included in the study. NovaLisa Measles IgG ELISA (NovaTec Immunodiagnostica GmbH®) kit was used to measure measles IgG antibodies in serological analyses. The research was conducted between Oct 2019 and Jun 2021. In the analysis of the data; descriptive statistics, chi-square analysis, and binary logistic regression analysis were used. The statistical significance level was accepted as P≤0.05.
Results: Measles seropositivity was detected in 103 (25.7%) of the women. This rate was found 5.5% in the 15-19 yr age group, 20.0% in the 20-24 yr age group, 14.5% in the 25-29 yr age group, 23.0% in the 30-34 yr age group, 42.3% in the 35-39 yr age group, 42.3% in the 40-44 yr age group and 37.5% in the 45-49 yr age group. In the logistic regression analysis, the rate of seropositivity was compared to those in the 15-19 yr age group; it was found to be 4.33 times (P=0.03) at the age of 20-24 yr, 12.71 times (P<0.001) at the age of 40-44 yr, and 10.40 times (P<0.001) at the age of 45-49.
Conclusion: Three out of every four babies born in our region are not adequately protected against measles.
1. Munoz FM, Englund JA (2001). Vaccines in pregnancy. Infect Dis Clin North Am, 15(1):253-271.
2. Borghi S, Bournazos S, Thulin NK, et al (2020). FcRn, but not FcγRs, drives ma-ternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci USA, 117(23):12943-12951.
3. Cetin Coban S, Temel F, Duman P, et al (2019). Prevalence of Protective Measles Virus Antibody Levels in Umbilical Cord Blood Samples and Sera of Mothers and Transplacental Transport Ratio in Turkey. Jpn J Infect Dis, 72(3):185-192.
4. Fu C, Lu L, Wu H, et al (2016). Placental an-tibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies. Sci Rep, 6:38874.
5. Dayan GH, Panero MS, Urquiza A, et al (2005). Rubella and measles seropreva-lence among women of childbearing age, Argentina, 2002. Epidemiol Infect, 133(5):861-9.
6. Cardemil CV, Jonas A, Beukes A, et al (2016). Measles immunity among preg-nant women aged 15-44 years in Namib-ia, 2008 and 2010. Int J Infect Dis, 49:189-95.
7. Qian XH, Yang P, Tang SZ (2010). Measles antibody level of productive women in Hongkou District of Shanghai Municipal. Zhongguo Yi Miao He Mian Yi, 16(2):146-7.
8. Nguyen CN, Nguyen QN, Dao TH, et al (2019). Association between measles an-tibodies in vaccinated and naturally in-fected mothers with protective antibodies and the occurrence of measles in their children: A cross-sectional study in the Bavi district of Hanoi. Asian Pac J Trop Med, 12(9):404-408.
9. Metintas S, Akgün Y, Arslantas D, et al (2002). Decay of maternally derived mea-sles antibody in central Turkey. Public Health, 116(1):50-4.
10. Yavuz T, Ozdemir I, Sencan I, et al (2005). Seroprevalence of varicella, measles and hepatitis B among female health care workers of childbearing age. Jpn J Infect Dis, 58(6):383-6.
11. Kutlu R, Civi S, Aslan R (2011). Tıp Fakültesi Kız Öğrencilerinde Kızamık, Kızamıkçık, Kabakulak ve Hepatit B Seroprevalansı. TAF Prev Med Bull, 10(5): 549-556.
12. Kader C, Kara M, Gocmen AY, et al (2017). Antibodies against vaccine preventable diseases in pregnant women measles, mumps, rubella, varicella and tetanus in Yozgat, Turkey. Konuralp Medical Journal, 9(2):106-111.
13. Bulut A, Ozdemir BN, Cetin S, et al (2015). İstanbul İli Sınırları İçindeki Bir Devlet Hastanesi Çalışanlarının Kızamık Sero-negatifliğinin Belirlenmesi. Acıbadem Ün-iversitesi Sağlık Bilimleri Dergisi (3):140-143.
14. Ozguler M, Saltık Gungor L, Kaygusuz T, et al (2016). Elazığ Eğitim ve Araştırma Has-tanesi Sağlık Çalışanlarında Hepatit A, Hepatit B, Kızamık ve Kızamıkçık Sero-prevalansı. Klimik Derg, 29(1):10-14.
15. WHO A report on the epidemiology of se-lected vaccine-preventable diseases in the European Region. No:1/2020. https://www.euro.who.int/__data/assets/pdf_file/0006/431745/EpiBrief_1_2020_EN.pdf?ua=1
16. WHO A report on the epidemiology of se-lected vaccine-preventable diseases in the European Region. No: 2/2020. https://www.euro.who.int/__data/assets/pdf_file/0010/463771/EpiBrief-No.-2-2020-eng.pdf
17. WHO Provisional monthly measles and ru-bella data. https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-in-sights/surveillance/monitoring/provisional-monthly-measles-and-rubella-data
18. Population and Demographics Database; Address Based Population Registration System (2018). Available from: https://data.tuik.gov.tr/Kategori/GetKategori?p=nufus-ve-demografi-109&dil=1
19. Shoda A, Hayashi M, Takayama N, et al (2011). Maternal screening and postpar-tum vaccination for measles infection in Japan: a cohort study. BJOG, 118(1):88-92.
20. Boulton ML, Wang X, Wagner AL, et al (2017). Measles Antibodies in Mother-Infant Dyads in Tianjin, China. J Infect Dis, 216(9):1122-1129.
21. Gieles NC, Mutsaerts EAML, Kwatra G, et al (2020). Measles seroprevalence in pregnant women in Soweto, South Afri-ca: a nested cohort study. Clin Microbiol In-fect, 26(4):515.e1-515.e4.
22. Zahraei SM, Mokhtari-Azad T, Izadi S, et al (2020). Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine, 38(2):235-241.
23. Congera P, Maraolo AE, Parente S, et al (2020). Measles in pregnant women: A systematic review of clinical outcomes and a meta-analysis of antibodies sero-prevalence. J Infect, 80(2):152-160.
24. Honarvar B, Moghadami M, Moattari A, et al (2013). Seroprevalence of anti-rubella and anti-measles IgG antibodies in preg-nant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS One, 8(1):e55043.
25. Marchi S, Monti M, Viviani S, et al (2019). Measles in pregnancy: a threat for Italian women? Hum Vaccin Immunother, 15(12):2851-2853.
26. Buzgan T (2011). Türkiye’de Dünden Bugüne Aşılama Politikaları. J Pediatr Inf, 5 (Suppl 1): 235-8.
27. Cosgun Y, Guldemir D, Coskun A, et al (2018). The importance of serological and molecular analyses for the diagnosis of measles cases and for meeting elimina-tion targets in Turkey from 2007 to 2015. Epidemiol Infect, 146(6):735-740.
28. Ministry of Health Health Statistics Year-book (2017). Available from: https://dosyasb.saglik.gov.tr/Eklenti/30148,ingilizcesiydijiv1pdf.pdf?0
29. Demographic and Health Survey (1993). Ministry of Health Turkey, Hacettepe University Institute of Population Studies, and Macro International Inc. Available from: http://hips.hacettepe.edu.tr/tr/1993_turkiye_nufus_ve_saglik_arastirmasi-83
30. Demographic and Health Survey (2008). Ministry of Health Turkey, Hacettepe University Institute of Population Studies, and Macro International Inc. Available from chrome- https://maldia.inonu.edu.tr/wp-con-tent/uploads/2022/10/BI%CC%87LDI%CC%87RI%CC%87-KI%CC%87TABI-TAM-metin-.pdf
31. Zhao H, Lu PS, Hu Y, et al (2010). Low ti-ters of measles antibody in mothers whose infants suffered from measles be-fore eligible age for measles vaccination. Virol J, 7:87.
32. Bodilis H, Goffinet F, Krivine A, et al (2014). Determinants of measles sero-prevalence among pregnant women in Paris, France. Clin Microbiol Infect, 20(8):O501-4.
2. Borghi S, Bournazos S, Thulin NK, et al (2020). FcRn, but not FcγRs, drives ma-ternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci USA, 117(23):12943-12951.
3. Cetin Coban S, Temel F, Duman P, et al (2019). Prevalence of Protective Measles Virus Antibody Levels in Umbilical Cord Blood Samples and Sera of Mothers and Transplacental Transport Ratio in Turkey. Jpn J Infect Dis, 72(3):185-192.
4. Fu C, Lu L, Wu H, et al (2016). Placental an-tibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies. Sci Rep, 6:38874.
5. Dayan GH, Panero MS, Urquiza A, et al (2005). Rubella and measles seropreva-lence among women of childbearing age, Argentina, 2002. Epidemiol Infect, 133(5):861-9.
6. Cardemil CV, Jonas A, Beukes A, et al (2016). Measles immunity among preg-nant women aged 15-44 years in Namib-ia, 2008 and 2010. Int J Infect Dis, 49:189-95.
7. Qian XH, Yang P, Tang SZ (2010). Measles antibody level of productive women in Hongkou District of Shanghai Municipal. Zhongguo Yi Miao He Mian Yi, 16(2):146-7.
8. Nguyen CN, Nguyen QN, Dao TH, et al (2019). Association between measles an-tibodies in vaccinated and naturally in-fected mothers with protective antibodies and the occurrence of measles in their children: A cross-sectional study in the Bavi district of Hanoi. Asian Pac J Trop Med, 12(9):404-408.
9. Metintas S, Akgün Y, Arslantas D, et al (2002). Decay of maternally derived mea-sles antibody in central Turkey. Public Health, 116(1):50-4.
10. Yavuz T, Ozdemir I, Sencan I, et al (2005). Seroprevalence of varicella, measles and hepatitis B among female health care workers of childbearing age. Jpn J Infect Dis, 58(6):383-6.
11. Kutlu R, Civi S, Aslan R (2011). Tıp Fakültesi Kız Öğrencilerinde Kızamık, Kızamıkçık, Kabakulak ve Hepatit B Seroprevalansı. TAF Prev Med Bull, 10(5): 549-556.
12. Kader C, Kara M, Gocmen AY, et al (2017). Antibodies against vaccine preventable diseases in pregnant women measles, mumps, rubella, varicella and tetanus in Yozgat, Turkey. Konuralp Medical Journal, 9(2):106-111.
13. Bulut A, Ozdemir BN, Cetin S, et al (2015). İstanbul İli Sınırları İçindeki Bir Devlet Hastanesi Çalışanlarının Kızamık Sero-negatifliğinin Belirlenmesi. Acıbadem Ün-iversitesi Sağlık Bilimleri Dergisi (3):140-143.
14. Ozguler M, Saltık Gungor L, Kaygusuz T, et al (2016). Elazığ Eğitim ve Araştırma Has-tanesi Sağlık Çalışanlarında Hepatit A, Hepatit B, Kızamık ve Kızamıkçık Sero-prevalansı. Klimik Derg, 29(1):10-14.
15. WHO A report on the epidemiology of se-lected vaccine-preventable diseases in the European Region. No:1/2020. https://www.euro.who.int/__data/assets/pdf_file/0006/431745/EpiBrief_1_2020_EN.pdf?ua=1
16. WHO A report on the epidemiology of se-lected vaccine-preventable diseases in the European Region. No: 2/2020. https://www.euro.who.int/__data/assets/pdf_file/0010/463771/EpiBrief-No.-2-2020-eng.pdf
17. WHO Provisional monthly measles and ru-bella data. https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-in-sights/surveillance/monitoring/provisional-monthly-measles-and-rubella-data
18. Population and Demographics Database; Address Based Population Registration System (2018). Available from: https://data.tuik.gov.tr/Kategori/GetKategori?p=nufus-ve-demografi-109&dil=1
19. Shoda A, Hayashi M, Takayama N, et al (2011). Maternal screening and postpar-tum vaccination for measles infection in Japan: a cohort study. BJOG, 118(1):88-92.
20. Boulton ML, Wang X, Wagner AL, et al (2017). Measles Antibodies in Mother-Infant Dyads in Tianjin, China. J Infect Dis, 216(9):1122-1129.
21. Gieles NC, Mutsaerts EAML, Kwatra G, et al (2020). Measles seroprevalence in pregnant women in Soweto, South Afri-ca: a nested cohort study. Clin Microbiol In-fect, 26(4):515.e1-515.e4.
22. Zahraei SM, Mokhtari-Azad T, Izadi S, et al (2020). Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine, 38(2):235-241.
23. Congera P, Maraolo AE, Parente S, et al (2020). Measles in pregnant women: A systematic review of clinical outcomes and a meta-analysis of antibodies sero-prevalence. J Infect, 80(2):152-160.
24. Honarvar B, Moghadami M, Moattari A, et al (2013). Seroprevalence of anti-rubella and anti-measles IgG antibodies in preg-nant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS One, 8(1):e55043.
25. Marchi S, Monti M, Viviani S, et al (2019). Measles in pregnancy: a threat for Italian women? Hum Vaccin Immunother, 15(12):2851-2853.
26. Buzgan T (2011). Türkiye’de Dünden Bugüne Aşılama Politikaları. J Pediatr Inf, 5 (Suppl 1): 235-8.
27. Cosgun Y, Guldemir D, Coskun A, et al (2018). The importance of serological and molecular analyses for the diagnosis of measles cases and for meeting elimina-tion targets in Turkey from 2007 to 2015. Epidemiol Infect, 146(6):735-740.
28. Ministry of Health Health Statistics Year-book (2017). Available from: https://dosyasb.saglik.gov.tr/Eklenti/30148,ingilizcesiydijiv1pdf.pdf?0
29. Demographic and Health Survey (1993). Ministry of Health Turkey, Hacettepe University Institute of Population Studies, and Macro International Inc. Available from: http://hips.hacettepe.edu.tr/tr/1993_turkiye_nufus_ve_saglik_arastirmasi-83
30. Demographic and Health Survey (2008). Ministry of Health Turkey, Hacettepe University Institute of Population Studies, and Macro International Inc. Available from chrome- https://maldia.inonu.edu.tr/wp-con-tent/uploads/2022/10/BI%CC%87LDI%CC%87RI%CC%87-KI%CC%87TABI-TAM-metin-.pdf
31. Zhao H, Lu PS, Hu Y, et al (2010). Low ti-ters of measles antibody in mothers whose infants suffered from measles be-fore eligible age for measles vaccination. Virol J, 7:87.
32. Bodilis H, Goffinet F, Krivine A, et al (2014). Determinants of measles sero-prevalence among pregnant women in Paris, France. Clin Microbiol Infect, 20(8):O501-4.
| Files | ||
| Issue | Vol 52 No 3 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i3.12142 | |
| Keywords | ||
| Women Measles Seroepidemiological study Enzyme-linked immunosorbent assay Immunity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Bugdaycı Yalcın BN, Sasmaz CT. Measles Seroprevalence and Related Factors in Women Aged 15-49 Years Old, in Mersin, Turkey. Iran J Public Health. 2023;52(3):593-602.
